UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

The New England journal of medicine, 2013-11, Vol.369 (19), p.1783-1796

2013

Volltextzugriff (PDF)

Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives

Leukemia research, 2014-10, Vol.38 (10), p.1145-1153

2014

Volltextzugriff (PDF)

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

American journal of hematology, 2013-05, Vol.88 (5), p.350-354

2013

Volltextzugriff (PDF)

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

Leukemia, 2013-06, Vol.27 (6), p.1316-1321

2013

Volltextzugriff (PDF)

A matched case–control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication

Clinical microbiology and infection, 2016-07, Vol.22 (7), p.636-641

2016

Volltextzugriff (PDF)

Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

Leukemia & lymphoma, 2017-01, Vol.58 (1), p.237-240

2017

Volltextzugriff (PDF)

CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment

Leukemia research, 2016-09, Vol.48, p.80-83

2016

Volltextzugriff (PDF)

Revealing stiffening and brittling of chronic myelogenous leukemia hematopoietic primary cells through their temporal response to shear stress

Physical biology, 2016-06, Vol.13 (3), p.03LT01-03LT01

2016

Volltextzugriff (PDF)

HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns

The Journal of infection, 2016-02, Vol.72 (2), p.214-222

2016

Volltextzugriff (PDF)

Historique de la leucémie myéloïde chronique : un paradigme de traitement du cancerCet article est entièrement dédié à la mémoire du Professeur John M. Goldman, décédé le 24 décembre 2013. This manuscript is entirely devoted to the memory of sir Professor John M. Goldman, deceased the 24th of December 2013

Bulletin du cancer, 2014-01, Vol.101 (1), p.56-67

2014

Volltextzugriff (PDF)

Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

Annals of hematology, 2017-03, Vol.96 (3), p.363-371

2017

Volltextzugriff (PDF)

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Haematologica (Roma), 2008-03, Vol.93 (3), p.455-458

2008

Volltextzugriff (PDF)

Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis

Transplant infectious disease, 2016-08, Vol.18 (4), p.595-600

2016

Volltextzugriff (PDF)

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

Leukemia, 2009-06, Vol.23 (6), p.1199-1201

2009

Volltextzugriff (PDF)

Historique de la leucémie myéloïde chronique: un paradigme de traitement du cancer

Bulletin du cancer, 2014, Vol.101 (1), p.56-67

2014

Volltextzugriff (PDF)

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

Leukemia, 2009-06, Vol.23 (6), p.1193-1196

2009

Volltextzugriff (PDF)

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management

Biology of blood and marrow transplantation, 2012, Vol.18 (2), p.S336-S336

2012

Volltextzugriff (PDF)

S881 PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY

HemaSphere, 2019-06, Vol.3 (S1), p.395-396

2019

Volltextzugriff (PDF)

PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

HemaSphere, 2019-06, Vol.3 (S1), p.158-n/a

2019

Volltextzugriff (PDF)

Highly Significant Impact of HLA-DRB3 and -DRB4 Matching on Different Unrelated allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Biology of blood and marrow transplantation, 2012, Vol.18 (2), p.S271-S271

2012

Volltextzugriff (PDF)

Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants from 10/10 HLA Unrelated Donors and Siblings

Biology of blood and marrow transplantation, 2012, Vol.18 (2), p.S327-S328

2012

Volltextzugriff (PDF)

Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

Leukemia, 2008-11, Vol.22 (11), p.2131-2134

2008

Volltextzugriff (PDF)

Preferential sensitivity of hematopoietic progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

Leukemia, 2008-11, Vol.22 (11), p.2131

2008

Volltextzugriff (PDF)

Phase II Prospective Multicenter Study of Treosulfan Based Reduced intensity Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor

Biology of blood and marrow transplantation, 2011, Vol.17 (2), p.S285-S285

2011

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(16)
Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Adult
(11)
Hematology
(11)
Middle Aged
(11)
Male
(10)
Female
(9)
Hematology, Oncology And Palliative Medicine
(9)
Life Sciences
(9)
Oncology
(9)
Aged
(8)
Cancer
(7)
Young Adult
(6)
Adolescent
(5)
Chronic Myeloid Leukemia
(4)
Dosage And Administration
(4)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(4)
Imatinib
(4)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

A matched case–control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication

Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment

Revealing stiffening and brittling of chronic myelogenous leukemia hematopoietic primary cells through their temporal response to shear stress

HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns

Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

Historique de la leucémie myéloïde chronique: un paradigme de traitement du cancer

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management

S881 PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY

PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

Highly Significant Impact of HLA-DRB3 and -DRB4 Matching on Different Unrelated allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants from 10/10 HLA Unrelated Donors and Siblings

Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

Preferential sensitivity of hematopoietic progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

Phase II Prospective Multicenter Study of Treosulfan Based Reduced intensity Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor

Suchergebnisse filtern